drugset / Trial / NCT02335346

An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)

NCT02335346

Phase 3 Completed 93 enrolled Eli Lilly and Company Shionogi · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of duloxetine in participants with osteoarthritis and knee pain. The study will last for 1 year.

Timeline

Start
2015-01
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral

Indications